New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - ascorbic acid 100mg;  ;  ;  ; copper (ii) sulfate pentahydrate 0.2mg; sodium percarbonate 90mg - soluble tablet - active: ascorbic acid 100mg       copper (ii) sulfate pentahydrate 0.2mg sodium percarbonate 90mg excipient: acacia erythrosine magnesium stearate maize starch menthol povidone purified talc saccharin sodium sodium bicarbonate tartaric acid

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; sodium stearylfumarate; lactose monohydrate; sodium bicarbonate - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - ramipril -

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; sodium stearylfumarate; lactose monohydrate; iron oxide red; sodium bicarbonate; pregelatinised maize starch - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - ramipril -

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; croscarmellose sodium; sodium bicarbonate; pregelatinised maize starch; iron oxide yellow; lactose monohydrate - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - ramipril -

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; sodium bicarbonate; pregelatinised maize starch; sodium stearylfumarate; lactose monohydrate - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - ramipril -

Canada - English - Health Canada

pascal international corporation - sodium fluoride; hydrogen fluoride; phosphoric acid - liquid - 1.95%; 0.75%; 1% - sodium fluoride 1.95%; hydrogen fluoride 0.75%; phosphoric acid 1% - dental agents